Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 18, 2016CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary Angioedema (HAE) attacks, for use in pediatric patients.
18 Jul 2016 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary...
-
Jun 23, 2016CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual Interlaken Leadership Awards.
23 Jun 2016 CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual...
-
Jun 20, 2016Driven by its promise to save lives, CSL Behring announced today that AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A, is now available nationwide.
20 Jun 2016 AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In clinical...
-
May 26, 2016CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
26 May 2016 AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In clinical...
-
May 24, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 24, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 16, 2016CSL Behring supports HAE Day through our continued partnership with HAEi & global awareness event sponsorships.
16 May 2016 CSL Behring joins the global HAE community today in recognition of the fifth annual hae day :-), an initiative led by HAEi, the international patient organization for C1-inhibitor...
-
May 13, 2016Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and Managing Director Paul Perreault with its 2016 Healthcare CEO Award.
13 May 2016 Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and Managing Director Paul Perreault...
-
May 11, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 11, 2016CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein].
11 May 2016 CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for IDELVION® [Coagulation Factor IX (Recombinant),...
-
May 11, 2016CSL Behring announced today that the European Commission has approved IDELVION® [albutrepenonacog alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
11 May 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days in the majority of patients, resulting in a median annualized spontaneous bleeding rate...
-
May 10, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 10, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 3, 2016In a keynote address on patient-centric leadership at the eyeforpharma Philadelphia Summit, CSL Chief Executive Officer and Managing Director Paul Perreault called on fellow industry leaders to do much more to connect with and learn from patients.
03 May 2016 A successful Pharma of the future requires a much different, authentic form of patient engagement Patient-centric leadership is fully embedded across CSL’s organization since its...
-
Apr 28, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 25, 2016CSL Behring today commemorated 100 years of developing and delivering innovative therapies to treat people with life-threatening medical conditions and help them live full lives.
25 Apr 2016 Locally, Company donates 100 trees to Valley Forge National Historical Park to mark centennial anniversary Shipment is a part of CSL Behring’s three year promise to provide more than...
-
Apr 25, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 13, 2016“Treatment for All is the Vision for All” is the World Federation of Hemophilia’s (WFH) global message for World Hemophilia Day this year (April 17, 2016). Demonstrating that purpose, the WFH and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 1.5 million international units (IUs) of its specialty biotherapeutics to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program and other WFH programs.
13 Apr 2016 More than 1.5 million international units (IUs) of treatments for Hemophilia A and/or von Willebrand Disease shipped in advance of World Hemophilia Day Shipment is a part of CSL Behring’
-
Apr 5, 2016CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]. IDELVION® is CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating hemophilia.
05 Apr 2016 CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION®...
-
Mar 21, 2016CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting recombinant albumin fusion protein for treating hemophilia B, is now available nationwide.
21 Mar 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL...
-
Mar 15, 2016A new webinar series addresses the unique needs of young adults living with Primary Immunodeficiency at a critical time when they are transitioning from teen to adulthood and taking responsibility for their own care.
15 Mar 2016 In honor of the upcoming World Primary Immunodeficiencies (PI) Week, CSL Behring is proud to sponsor Immune Deficiency Foundation’s new PI Voices, Young Adult Webinar Series. The...
-
Mar 15, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 9, 2016CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy ObjectivesPatients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest round of LEAD Grant awards. CSL Behring established the LEAD grant program in 2008 to help support the important advocacy work of patient groups in tackling complex legislative and public policy issues.
09 Mar 2016 Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest...